Get the Stockscreener App
27.44
0.83%
-0.23
After Hours:
27.38
-0.06
-0.22%
Cue Biopharma Inc stock is traded at $27.44, with a volume of 50,415.
It is down -0.83% in the last 24 hours and up +3.16% over the past month.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
See More
Previous Close:
$27.67
Open:
$27.55
24h Volume:
50,415
Relative Volume:
0.34
Market Cap:
$199.34M
Revenue:
$32.73M
Net Income/Loss:
$-19.52M
P/E Ratio:
-4.9643
EPS:
-5.5275
Net Cash Flow:
$-24.61M
1W Performance:
-1.58%
1M Performance:
+3.16%
6M Performance:
+202.57%
1Y Performance:
+16.52%
1-Day Range:
$27.02
$27.95
1-Week Range:
$25.01
$29.28
52-Week Range:
$4.971
$45.50
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
27.44 | 178.78M | 32.73M | -19.52M | -24.61M | -5.5275 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Law firm investigates Cue Biopharma's directors for possible breach of fiduciary duties. - Pluang
Shao-Lee Lin Discloses Investment at Cue Biopharma with 6.2% Stake - TradingView
Cue Biopharma (CUE) CEO builds stake with stock awards and cheap warrants - Stock Titan
Cue Biopharma, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
Driehaus Capital Management Acquires New Stake in Cue Biopharma Inc (CUE) - GuruFocus
Cue Biopharma VP Michael Meluzio disposes of $169,323 in stock - Investing.com
Cue Biopharma VP Michael Meluzio disposes of $169,323 in stock By Investing.com - Investing.com South Africa
Cue Biopharma legal chief sells $265,627 in common stock - Investing.com
Cue Biopharma legal chief sells $265,627 in common stock By Investing.com - Investing.com Canada
Cue Biopharma (NASDAQ:CUE) VP Michael Vincent Meluzio Sells 5,628 Shares of Stock - MarketBeat
Insider Selling: Cue Biopharma (NASDAQ:CUE) Insider Sells $265,664.61 in Stock - MarketBeat
Cue Biopharma (NASDAQ: CUE) exec's tax sell-to-cover after equity grant - Stock Titan
Cue Biopharma (CUE) Q2 Results Highlight High Price-to-Sales Ami - GuruFocus
Cue Biopharma (CUE) Leaps 10.04% to $34.2, Testing Key Resistance at $35.91Seasonality Effect - Vinanet
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits
Cue Biopharma (NASDAQ:CUE) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Cue Biopharma CEO Lin sells shares worth $1.6 million By Investing.com - Investing.com Canada
Cue Biopharma CEO Lin sells shares worth $1.6 million - Investing.com
Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells $1,084,000.00 in Stock - MarketBeat
Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells 18,258 Shares - MarketBeat
Insider plans 58,258-share stock sale (NASDAQ: CUE) under Rule 144 - Stock Titan
Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $22.45 EPS - MarketBeat
Cue Biopharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cue Biopharma Q2 loss widens to $153.1M on non-cash charges - scanx.trade
Is Cue Biopharma Inc (CUE) Facing Financial Strain After Q2 Loss - GuruFocus
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Cue Biopharma Q2 revenue more than doubles, net loss widens on one-time charges - TradingView
Cue Biopharma Raises $50M for CUE-221 Food Allergy Program - Stock Titan
Cue Biopharma Stock (CUE) Opinions on Management Changes and Phase 2 Data Prospects - Quiver Quantitative
Driehaus Capital discloses 6.96% Cue Biopharma (CUE) holding in Schedule 13G - Stock Titan
Cue Biopharma Inc. (NASDAQ: CUE)Dividends - intelligentinvestor.com.au
Cue Biopharma, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
Cue Biopharma (CUE) registers 1.51M shares for stockholder resale after $50M raise - Stock Titan
Cue Biopharma (CUE) Expected to Announce Earnings on Tuesday - marketbeat.com
Cue Biopharma (NASDAQ:CUE) Trading Down 3.8%Should You Sell? - MarketBeat
Cue Biopharma (CUE) Holds Steady Near $27 as Biotech Sector Digests MomentumEMA Signal - dars.gov.et
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits
Cue Biopharma, Inc. expected to post a loss of $1.69 a shareEarnings Preview - TradingView
Cue Biopharma Inc (CUE) Stock News Today - TradingKey
Cue Biopharma Inc (CUE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cue Biopharma Appoints Veteran James Ahlers as CFO - The Globe and Mail
Cue Biopharma Appoints James Ahlers as Chief Financial Officer – SEC 8-K Filing Details - Minichart
Cue appoints James Ahlers as Chief Financial Officer - TradingView
Cue Biopharma (CUE) hires James Ahlers as CFO with equity and severance package - Stock Titan
Cue Biopharma, Inc. Announces Appointment of James Ahlers as Principal Financial Officer, Effective July 30, 2026 - marketscreener.com
Cue Biopharma names James Ahlers as chief financial officer By Investing.com - Investing.com Nigeria
Cue Biopharma Names James Ahlers CFO - Moomoo
Cue Biopharma names James Ahlers as chief financial officer - Investing.com
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission - Yahoo Finance
Cue Biopharma appoints James M. Ahlers as CFO to steer clinical-stage growth - scanx.trade
Cue Biopharma Inc (CUE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cue Biopharma Inc Stock (CUE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ray Sumita | Chief Legal Compliance Officer |
Aug 13 '26 |
Sale |
30.09 |
8,829 |
265,628 |
118,545 |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer |
Aug 13 '26 |
Option Exercise |
0.00 |
13,647 |
0 |
54,589 |
| Meluzio Michael Vincent | VP, Prin. Accounting Officer |
Aug 13 '26 |
Sale |
30.09 |
5,628 |
169,324 |
48,961 |
| Lin Shao-Lee | Chief Executive Officer |
Aug 12 '26 |
Option Exercise |
0.00 |
109,179 |
0 |
764,253 |
| Lin Shao-Lee | Chief Executive Officer |
Aug 12 '26 |
Sale |
27.10 |
40,000 |
1,083,989 |
724,253 |
| Lin Shao-Lee | Chief Executive Officer |
Aug 13 '26 |
Sale |
28.62 |
18,258 |
522,573 |
705,995 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):